Skip to main content

Drug Interactions between Abilify and nafcillin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

nafcillin ARIPiprazole

Applies to: nafcillin and Abilify (aripiprazole)

MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of aripiprazole and its active metabolite, dehydro-aripiprazole. Clinical and in vitro data indicate that aripiprazole is extensively metabolized in the liver primarily via three enzymatic pathways (dehydrogenation, hydroxylation, and N-dealkylation) mediated by CYP450 2D6 and 3A4. When aripiprazole 30 mg once daily was coadministered with the potent CYP450 3A4 inducer carbamazepine at 200 mg twice daily in schizophrenic patients, mean aripiprazole peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 68% and 73%, respectively, compared to administration of aripiprazole alone. Likewise, mean Cmax and AUC of dehydro-aripiprazole were decreased by 69% and 71%, respectively, in the presence of carbamazepine. The interaction has not been studied with other, less potent inducers.

MANAGEMENT: Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary. The prescribing information for individual aripiprazole products should be consulted for specific recommendations regarding concomitant use with CYP450 3A4 inducers.

References (10)
  1. (2022) "Product Information. Abilify (ARIPiprazole)." Bristol-Myers Squibb
  2. (2023) "Product Information. Abilify Maintena (ARIPiprazole)." Otsuka American Pharmaceuticals Inc
  3. (2022) "Product Information. Aristada (ARIPiprazole)." Alkermes, Inc
  4. (2022) "Product Information. Aristada Initio (ARIPiprazole)." Alkermes, Inc
  5. (2021) "Product Information. Abilify (aripiprazole)." Otsuka Pharmaceutical Co Ltd
  6. (2021) "Product Information. Abilify Maintena (aripiprazole)." Otsuka Pharmaceutical Co Ltd
  7. (2023) "Product Information. Abilify (aripiprazole)." Otsuka Pharmaceuticals (U.K.) Ltd
  8. (2022) "Product Information. Abilify Maintena (aripiprazole)." Otsuka Pharmaceuticals (U.K.) Ltd
  9. (2022) "Product Information. Abilify (ARIPiprazole)." Otsuka Australia Pharmaceutical Pty Ltd
  10. (2022) "Product Information. Abilify Maintena (ARIPiprazole)." Lundbeck Australia Pty Ltd

Drug and food interactions

Moderate

nafcillin food

Applies to: nafcillin

ADJUST DOSING INTERVAL: Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food. The therapeutic effect of the antimicrobial may be reduced.

MANAGEMENT: The interacting penicillin should be administered one hour before or two hours after meals. Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.

References (6)
  1. Neu HC (1974) "Antimicrobial activity and human pharmacology of amoxicillin." J Infect Dis, 129, s123-31
  2. Welling PG, Huang H, Koch PA, Madsen PO (1977) "Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects." J Pharm Sci, 66, p. 549-52
  3. McCarthy CG, Finland M (1960) "Absorption and excretion of four penicillins." N Engl J Med, 263, p. 315-26
  4. Cronk GA, Wheatley WB, Fellers GF, Albright H (1960) "The relationship of food intake to the absorption of potassium alpha-phenoxyethyl penicillin and potassium phenoxymethyl penicillin from the gastrointestinal tract." Am J Med Sci, 240, p. 219-25
  5. Klein JO, Sabath LD, Finland M (1963) "Laboratory studies on oxacillin. I: in vitro activity against staphylococci and some other bacterial pathogens. II: absorption and urinary excretion in normal young." Am J Med Sci, 245, p. 399-411
  6. Neuvonen PJ, Elonen E, Pentikainen PJ (1977) "Comparative effect of food on absorption of ampicillin and pivampicillin." J Int Med Res, 5, p. 71-6
Moderate

ARIPiprazole food

Applies to: Abilify (aripiprazole)

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References (4)
  1. Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  4. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer